Q1 2024 EPS Estimates for BioXcel Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:BTAI)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Free Report) - HC Wainwright upped their Q1 2024 earnings per share estimates for shares of BioXcel Therapeutics in a research note issued to investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.69) per share for the quarter, up from their prior estimate of ($0.93). HC Wainwright has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for BioXcel Therapeutics' current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for BioXcel Therapeutics' Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.59) EPS, Q4 2024 earnings at ($0.54) EPS and FY2024 earnings at ($2.42) EPS.

BioXcel Therapeutics (NASDAQ:BTAI - Get Free Report) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.22. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The company had revenue of $0.38 million during the quarter, compared to analyst estimates of $1.17 million.

Several other equities research analysts have also commented on the company. Canaccord Genuity Group cut their price objective on BioXcel Therapeutics from $18.00 to $7.00 and set a "buy" rating for the company in a research note on Thursday, March 14th. UBS Group restated a "neutral" rating and issued a $4.00 price target (down from $9.00) on shares of BioXcel Therapeutics in a research report on Wednesday, February 21st. Finally, Bank of America dropped their price target on BioXcel Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday, March 13th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $16.86.

BioXcel Therapeutics Trading Down 1.5 %

NASDAQ:BTAI traded down $0.04 during trading hours on Thursday, hitting $2.55. 244,513 shares of the stock were exchanged, compared to its average volume of 1,357,663. BioXcel Therapeutics has a 52-week low of $1.91 and a 52-week high of $29.56. The firm's fifty day moving average price is $2.88 and its 200 day moving average price is $3.17. The company has a market cap of $77.98 million, a P/E ratio of -0.41 and a beta of 0.40.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in BioXcel Therapeutics by 0.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 143,893 shares of the company's stock worth $2,685,000 after purchasing an additional 611 shares in the last quarter. Legal & General Group Plc lifted its stake in BioXcel Therapeutics by 7.5% during the fourth quarter. Legal & General Group Plc now owns 9,678 shares of the company's stock worth $208,000 after purchasing an additional 678 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in BioXcel Therapeutics by 5.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 14,747 shares of the company's stock worth $195,000 after purchasing an additional 794 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in BioXcel Therapeutics by 9.5% during the fourth quarter. JPMorgan Chase & Co. now owns 11,595 shares of the company's stock worth $249,000 after purchasing an additional 1,006 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in BioXcel Therapeutics by 205.2% during the first quarter. Tower Research Capital LLC TRC now owns 1,529 shares of the company's stock worth $29,000 after purchasing an additional 1,028 shares in the last quarter. 30.68% of the stock is currently owned by institutional investors and hedge funds.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.